Penumbra has received a CE mark for its latest computer-assisted vacuum thrombectomy (CAVT) technologies in Europe.

These products, Lightning Flash 2.0 and Lightning Bolt 7, are engineered to enhance patient care by optimising the thrombectomy process.

Lightning Flash 2.0 represents the latest in mechanical thrombectomy systems, specifically tailored for venous and pulmonary thrombus management.

It incorporates Penumbra's Lightning Intelligent Aspiration technology, which utilises advanced dual clot detection algorithms that employ both pressure and flow-based methods to discern blood clots from blood flow.

The design of the Lightning Flash 2.0 catheter features MaxID hypotube technology, which enables a large inner diameter akin to that of large-bore catheters while maintaining a slimmer profile.

The catheter's soft, atraumatic tip is crafted to navigate the body's intricate anatomy, enabling rapid clot removal with minimal blood loss.

Moreover, the system's audio-visual feedback streamlines the procedure, granting physicians a clearer insight into the catheter's tip activity during thrombectomy.

Penumbra chief medical officer James Benenati said: “Based on outcomes from our clinical trials and physicians using our devices globally, our CAVT technologies have greatly improved our ability to rapidly and safely remove clots in the vascular system.

"With quicker procedures and more efficient clot removal, we have improved outcomes while demonstrating a high level of safety.”

Penumbra's Lightning Bolt 7 is said to be the market's most potent arterial thrombectomy system. Introduced in June 2023, it brings a new approach to blood clot removal, termed modulated aspiration.

This technique combines the company's Lightning Intelligent Aspiration technology with a microprocessor algorithm.

Lightning Bolt 7 is adept at swiftly extracting large, fibrous blood clots found in arteries, with minimal blood loss, thereby addressing acute limb ischemia, visceral occlusions and hibernating thrombus.

It is designed to differentiate between blood clots and blood flow, enhancing the efficacy of arterial thrombectomy procedures.

"Penumbra secures CE mark for CAVT technologies in Europe" was originally created and published by Medical Device Network, a GlobalData owned brand.

 

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.